옵션 체인은 다양한 행사가격과 만기일에 대한 10x Genomics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 10x Genomics에 대한 시장 심리를 평가합니다..

10x Genomics (NASDAQ:TXG) 주식, 옵션 체인

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Hedge Funds

Tech

AVGO

MSFT

레이 달리오의 브릿지워터 어소시에이츠가 최근 마이크로소프트(NASDAQ:MSFT)의 지분을 20% 줄였다. 이는 오랜 기간 동안 기술의 주요 주자로 간주되어온 주식의 주목할 만한 감소이다.

레이 달리오의 브리지워터, MS 주식 지분 20% 축소 - 대형 기술주의 매력이 사라지고 있는가?

Broad U.S. Equity ETFs

Education

Specialty ETFs

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

ARKW

BEAM

GTLB

목요일, 캐시 우드의 아크 인베스트(Ark Invest)가 자율주행 택시 부문에서 테슬라(NASDAQ:TSLA)의 잠재력에 대한 최근 낙관적인 전망에도 불구하고 이 회사의 지분을 축소하는 중요한 움직임을 보였다.

캐시 우드의 아크 인베스트는 긍정적인 자율주행 전망에도 $800만 테슬라 주식 매도

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

WIIM

GDS shares are trading higher following a Tuesday report suggesting the company is considering an IPO of its data center assets in China.

Bryan Lanza, a former adviser to President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a> and now a lobbyist for the cannabis industry, says the incoming administration may pave the way for significant marijuana policy reforms. However, he cautions that full <a href="https://www.benzinga.com/topic/cannabis-legalization">federal legalization of cannabis</a> is unlikely within the next four years.
In a recent <a href="https://www.youtube.com/watch?v=TNTVkxkO01E">interview</a><a href="https://www.youtube.com/@InsideCultivation"> </a>on the Inside Cultivation podcast, Lanza, who served on Trump's 2016 transition team and worked on his 2024 campaign, discussed what the future could hold for federal cannabis policy under a Trump White House.
"This is the first time that we have a Republican president that has given us a pathway to what he's comfortable with," Lanza said, referring to Trump's unexpected <a href="https://www.benzinga.com/markets/cannabis/24/09/40776937/trump-joins-millions-of-americans-who-support-rescheduling-cannabis-weed-industry-responds-to-fo">cannabis-related remarks</a> during the campaign when he described the moment as a "good opportunity" for the industry to make progress. During his campaign, Trump <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">said he'd reschedule cannabis</a>, which would provide access to banking services for marijuana companies and open the doors to scientific research.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41787490/donald-trumps-evolving-stance-on-marijuana-is-cannabis-legalization-finally-on-his-agenda">Donald Trump&#8217;s Evolving Stance On Marijuana: Is Cannabis Legalization Finally On His Agenda?</a>
Lanza predicted that the ongoing process to reschedule cannabis under federal law would likely conclude in early 2025, aligning with Trump's stated support for regulating <a href="https://www.benzinga.com/topic/medical-cannabis">medical marijuana</a>. 
"At the end of the day, when a decision is made, he expects his team to execute. And President Trump has made a decision where he is in this space, and it's incumbent on those who go work for him to know that's what he wants to execute, and they're going to execute," Lanza said.
&#8220;Are there going to be obstacles? There's always obstacles in everything, right?" he said, adding that there are "obviously coalitions that are going to be against this." Lanza mentioned big Pharma as one of them.
Trump's potential support for reforms could influence Congress to act on measures such as banking protections for cannabis businesses. Yet, Lanza remains skeptical about achieving full legalization. "Four years is not long enough to accomplish all the goals we need to do in the cannabis space," he said while suggesting that a unified front is the best way to achieve progress.
&#8220;If you splinter off and you have too many different voices going in too many different directions, I guarantee you that is a recipe for failure—and it is a missed opportunity, because Trump is giving you his roadmap," Lanza said.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/12/42655999/house-ethics-committee-alleges-matt-gaetz-violated-laws-releases-report-on-misconduct">House Ethics Committee Alleges Matt Gaetz Violated Laws, Releases Report On Misconduct</a></li>
</ul>
Photo: Anna Moneymaker/Shutterstock.com

Cannabis

Government

Politics

Legal

Trump Is First 'Republican President' With A Pathway To Cannabis Reform, Says Former Adviser

PG&amp;E's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) short percent of float has risen 21.56% since its last report. The company recently reported that it has 39.06 million shares sold short, which is 2.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PG&amp;E Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735233322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PG&amp;E has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing PG&amp;E's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PG&amp;E's peer group average for short interest as a percentage of float is 2.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About PG&E?

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has risen 3.64% since its last report. The company recently reported that it has 11.55 million shares sold short, which is 1.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735233317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into KKR's Recent Short Interest

Sony Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) short percent of float has risen 8.33% since its last report. The company recently reported that it has 7.84 million shares sold short, which is 0.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sony Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735233312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sony Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sony Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sony Gr's peer group average for short interest as a percentage of float is 4.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Sony Group Corporation American Depositary Shares

SONY

Looking Into Sony Gr's Recent Short Interest

LNKS

Linkers Industries Shares Halted To The Downside; Stock Now Down -35.56%

Billionaire investor Stanley Druckenmiller recently made a big investment in Broadcom (AVGO), <a href="https://www.benzinga.com/24/12/42659876/stanley-druckenmiller-pours-funds-into-1-trillion-company-already-trading-up-100?adt_ei=%7B%7Bemail%7D%7D&amp;he=%7B%7Bemail%7D%7D">increasing his stake to 239,980 shares</a>.&nbsp;
That stake, up 35% since September, is worth almost $56 million, one of the largest holdings in Druckenmiller&#8217;s private family fund. Now, Broadcom shares have surged almost 70% recently, so the stock is probably due for a breather.
But Druckenmiller&#8217;s big bet suggests there&#8217;s plenty of upside potential left.
I anticipate some consolidation into January and perhaps even February before the stock makes its next big move. That&#8217;s why the trade to make on Broadcom in the near term is a short iron condor.
Let me show you.
The short iron condor is a combination of a short call spread and a short put spread – a trade that sells premium on both the lower and upper bounds of price under the notion that prices remain rangebound in consolidation of strength.
As a result, the position loses the value we collected for selling it, and we are able to buy it back at a cheaper cost and keep the difference as profit for holding the spreads over time.&nbsp;
Here&#8217;s the trade structure I&#8217;m looking at:
<ul>
<li>Sell to open 1 AVGO 17 Jan 260 calls </li>
<li>Buy to open 1 AVGO 17 Jan 265 calls </li>
<li>Buy to open 1 AVGO 17 Jan 220 puts </li>
<li>Sell to open 1 AVGO 17 Jan 215 puts </li>
</ul>
At this writing, the credit collected is $1.67 and this number represents the total profit for the position.&nbsp;&nbsp;
The reason I chose these particular strikes is because of AVGO&#8217;s support and resistance levels. The relative resistance zone currently sits right around $250, and from here we should consolidate (move around within a range of price for a period of time). The relative support is near $225.
This strategy provides four outcomes to exit the trade:&nbsp;
<ol>
<li>Buy back the iron condor as its value erodes – I like to collect 50% of the original collected premium, in general. </li>
<li>Buy back the iron condor within ten days of expiration, especially if there is no movement in price. </li>
<li>If the prices spike above the short strikes (in this case, above $260 or below $220) for more than 3 days: exit the position, irrespective of where profits sit. </li>
<li>Buy back the iron condor if it moves above your threshold for loss – usually between 35%-50% above the collected premium.</li>
</ol>
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?utm_source=WebRD-1227">Last Chance to Save 65% – End-of-Year Sale Ends December 31!</a>
Transform your trading strategy with Benzinga Edge. Get exclusive stock picks, daily trade setups, and real-time alerts. Last chance to save 65%—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?utm_source=WebRD-1227">don't miss the End-of-Year Sale before it's gone!</a>
Image via Flickr

Opinion

A Billionaire Set Us Up Perfectly for This Options Trade

Rumble shares are trading higher. The stock may be moving on continued strength after the company, last week, announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

Reported Earlier: Mastercard SpendingPulse Says U.S. Retail Sales Excluding Automotive Increased 3.8% YoY From Nov 1 Through Dec 24; U.S. Online Retail Sales In Holiday Season Grew 6.7% YoY, Whereas In-store Sales Increased 2.9%

RGTI

Rigetti Computing shares are trading higher amid continued momentum in quantum stocks.

AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) will release earnings results for its second quarter, after the closing bell on <a href="https://www.benzinga.com/quote/air/earnings">Tuesday, Jan. 7, 2025</a>.
Analysts expect the Wood Dale, Illinois-based company to report quarterly earnings at 84 cents per share, up from 81 cents per share in the year-ago period. AAR projects to report revenue of $654.09 million for the recent quarter, compared to $545.4 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 20, AAR announced divestiture of non-core Landing Gear Overhaul business to optimize portfolio.
AAR shares fell 0.1% to trade at $60.87 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/AIR/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>RBC Capital analyst Ken Herbert reiterated an Outperform rating with a price target of $75 on Nov. 4. This analyst has an accuracy rate of 64%.</li>
<li>Benchmark analyst Josh Sullivan reiterated a Buy rating with a price target of $83 on Oct. 4. This analyst has an accuracy rate of 85%.</li>
<li>Stifel analyst Bert Subin maintained a Buy rating and decreased the price target from $86 to $85 on July 19. This analyst has an accuracy rate of 62%.</li>
<li>William Blair analyst Louie DiPalma initiated coverage on the stock with an Outperform rating on Jan. 29. This analyst has an accuracy rate of 72%.</li>
</ul>

Considering buying AIR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26110243/image-211-1024x590.png" alt="" class="wp-image-707873" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26110243/image-211-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26110243/image-211-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26110243/image-211-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26110243/image-211.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684694/top-2-health-care-stocks-you-may-want-to-dump-this-quarter">Top 2 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

AAR Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Rumble shares are trading higher. The stock may be moving on continued strength after the company, on Friday, announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

Fans of global superstar Beyoncé who missed her Christmas Day NFL halftime performance, or want to relive the moment, are in for a treat. Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is set to feature one of the standout moments from its <a href="https://www.benzinga.com/general/sports/24/12/42512587/netflix-analyst-say-its-only-investable-media-stock-projects-150-million-nfl-christmas-day-boost">debut NFL game streams.</a>
What Happened: For the first time ever, Netflix <a href="https://www.benzinga.com/24/12/42653325/exclusive-netflix-to-have-merry-christmas-with-nfl-games-will-viewers-tune-in-60-say">streamed two live</a> NFL games on Christmas Day. The games, which are part of a three-year deal, saw Netflix as the exclusive home of the Kansas City Chiefs at Pittsburgh Steelers and Baltimore Ravens at Houston Texans matchups on Wednesday.
Beyoncé <a href="https://about.netflix.com/en/news/beyonce-delivers-epic-gift-of-a-halftime-performance-beyonce-bowl-is-coming">performed </a>a 12-minute set during halftime of the Ravens and Texans game, which took place in her hometown of Houston.
Being labeled the "Beyoncé Bowl" by Netflix, the halftime performance featured the first-ever live performances of songs from the singer's "Cowboy Carter" album.
The performance featured guest appearances by Shaboozey, Post Malone and Beyoncé's daughter Blue Ivy Carter.
Netflix announced that "Beyoncé Bowl" will be released as a standalone special on the streaming platform later this week.
The streaming company did not provide an exact date or additional details on whether the special would just be the halftime performance or include behind-the-scenes or additional footage.
Read Also:<a href="https://www.benzinga.com/general/entertainment/24/12/42563662/streamers-max-paramount-won-november-heres-why-analyst-expects-netflix-amazon-to-win-december"> Streamers Max, Paramount+ Won November: Here&#8217;s Why Analyst Expects Netflix, Amazon To Win December</a>
Why It's Important: Netflix appears poised to leverage the star power of one of the world's most popular singers, featured during halftime of its inaugural Christmas Day NFL games.
Beyoncé previously performed at halftime of Super Bowl XLVII in 2013, a performance that featured her Destiny's Child bandmates Kelly Rowland and Michelle Williams, and in 2016 with Coldplay and Bruno Mars at Super Bowl 50. Both halftime performances rank among the most watched in NFL history. &nbsp;
The singer teased that there is more coming from her next month. An Instagram <a href="https://www.instagram.com/p/DEBPJl1yvvp/">post </a>featured Beyoncé on a horse with an American flag and ends with the screen showing the date of Jan. 14, 2025.
While the teaser post may not be in relation to Netflix, the streaming company has more coming from Beyoncé.
The singer and streamer signed a $60 million <a href="https://variety.com/2019/music/news/beyonce-netflix-deal-1203193729/">deal </a>in 2019, which included "Homecoming," a documentary concert film about the singer's 2018 Coachella performance.
Several reports suggest that the NFL Christmas Day performance and subsequent "Beyoncé Bowl" release are the second of the three projects, leaving one more Netflix special coming from the global superstar.
NFLX Price Action: Netflix stock is down 1.2% to $920.78 on Monday versus a 52-week trading range of $461.86 to $941.75. Netflix stock is up 97% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/24/12/42628116/netflix-adds-womens-world-cup-media-rights-from-football-to-futbol-streamer-all-in-on-live-sports">Netflix Adds Women&#8217;s World Cup Media Rights: From Football To Futbol, Streamer All-In On Live Sports</a></li>
</ul>
Photo: Shutterstock

Entertainment

Sports

NFLX

Netflix To Release 'Beyoncé Bowl' NFL Halftime Performance As Standalone Special

BOOT

DLTR

FIVE

ULTA

Shares of retail stocks are trading higher in possible reaction to Mastercard SpendingPulse data, which showed US retail sales grew 3.8% in the holiday season.

Wedbush analyst Daniel Ives maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $300 to $325.

AAPL

Wedbush Maintains Outperform on Apple, Raises Price Target to $325

Macro Notification

General

Putin Says Russia Is Ready To Supply Gas Via Ukraine To Any Counter-Agent, But That's Impossible Due To Lawsuit From Kyiv; Ukraine Punishes Europe By Shutting Russian Gas Transit; Gas Prices In Europe Will Rise

WiMi Hologram Cloud Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42686949/wimi-develops-a-quantum-technology-based-random-access-memory-architecture" rel="noreferrer noopener">trading higher on Thursday.</a>
The firm has announced the development of a Quantum Technology-Based Random Access Memory Architecture, known as QRAM.
QRAM combines quantum logic gates such as the CNOT gate, V gate, and V+ gate to perform logical operations like AND, OR, NOT, and NOR within quantum systems, harnessing quantum properties like superposition and entanglement for enhanced computational efficiency.
Unlike traditional RAM, which operates sequentially, QRAM leverages quantum superposition to enable parallel data access, significantly speeding up operations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/24/12/42686735/azerbaijan-airliner-crash-kills-38-weather-russia-under-scrutiny" rel="noreferrer noopener">Azerbaijan Airliner Crash Kills 38: Weather, Russia Under Scrutiny</a>
Quantum entanglement further improves efficiency by allowing multiple qubits to be correlated without direct communication, resulting in faster data transfer and processing. This design dramatically enhances computational performance, especially for large-scale tasks like molecular simulations and complex optimizations.
WiMi's QRAM architecture also integrates a quantum error correction mechanism, which ensures that qubit states remain stable and accurate during data read and write operations. This feature is crucial for maintaining reliability in quantum computing systems, where external disturbances can easily cause errors.
The QRAM system is highly compatible with quantum processing units, enabling smooth data transmission between memory and processors, which optimizes overall computational efficiency. With its ability to handle large datasets, QRAM is poised to advance quantum machine learning and quantum encryption applications, providing faster training and secure data transmission.
WiMi&#8217;s development of QRAM marks a significant step forward in quantum technology, setting the stage for a future where quantum computers play a crucial role in solving complex real-world problems.
Price Action: WIMI shares are trading higher by 13.3% to $1.27 at last check Thursday.
Also Read:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42356227/spacexs-22488-satellite-expansion-challenged-over-elon-musks-russian-connections-and-environmental-risks" target="_blank" rel="noreferrer noopener">SpaceX's Satellite Expansion Challenged: Ukrainian-Americans Allege Elon Musk's Russian Ties And Environmental Risks In FCC Petition</a></li>
</ul>

Movers

WIMI

WiMi Develops Quantum Technology-Based QRAM Architecture, Shares Surge

Linkers Industries Shares Resume Trade

U.S. stocks turned higher midway through trading, with the Dow Jones index gaining around 50 points on Thursday.
The Dow traded up 0.12% to 43,347.41 while the NASDAQ rose 0.03% to 20,037.71. The S&amp;P 500 also rose, gaining, 0.05% to 6,042.96.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Health care shares rose by just 0.1% on Thursday.
In trading on Thursday, information technology shares dipped by 0.4%.
Top Headline
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares shot up 31% to $7.16. On Thursday, SEALSQ announced the launch of SEALQUANTUM.com Lab, a research hub designed to help businesses transition to quantum-safe encryption</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 155% to $0.5600 after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares were also up, gaining 90% to $2.71 after it reported a 43% year-on-year increase in November bookings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neuphoria Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEUP#NASDAQ">NEUP</a>) shares dropped 38% to $4.10.</li>
<li>Shares of Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) were down 34% to $4.66.</li>
<li>SaverOne 2014 Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) was down, falling 30% to $1.0501.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $70.25 while gold traded up 0.6% at $2,651.20.
Silver traded up 0.6% to $30.450 on Thursday, while copper rose 0.6% to $4.1335.
Euro zone
In Europe, markets in Germany, France, London, Spain and Switzerland are closed for the Boxing Day holiday.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 1.12%, China's Shanghai Composite Index gaining 0.14% and India's BSE Sensex falling 0.01%.
Economics
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684254/top-3-utilities-stocks-youll-regret-missing-in-december">Top 3 Utilities Stocks You&#8217;ll Regret Missing In December</a></li>
</ul>

Eurozone

Commodities

Intraday Update

BAOS

LAES

NEUP

SPRC

SVRE

ZCAR

Dow Gains 50 Points, SEALSQ Shares Plummet

Mark Zuckerberg recently shared a glimpse into his personal and professional life through a lighthearted Instagram video posted by the Chan Zuckerberg Initiative. While the video focused on the couple&#8217;s nonprofit work and fun personal anecdotes, many viewers couldn't help but notice the stunning watch on Zuckerberg's wrist – a Patek Philippe Grand Complications 5303R in 18k rose gold, worth a jaw-dropping $1.2 million.
<a href="https://www.instagram.com/reel/DDpSq-DRpxb">https://www.instagram.com/reel/DDpSq-DRpxb</a>
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
This luxurious timepiece isn't just an accessory; it's a masterpiece of craftsmanship. The Patek Philippe Minute Repeater Skeleton 5303R is a rare creation that puts its intricate mechanics on full display. The watch's standout feature is its open sapphire dial, where you can see the hammers and gongs of the minute repeater in action – essentially, the watch chimes the time in an audible format. Its rose-gold case, paired with white-gold decorative details and a black alligator leather strap, makes it as much a work of art as it is an engineering feat.
In the <a href="https://www.instagram.com/reel/DDpSq-DRpxb/">video</a>, Zuckerberg and his wife, <a href="https://www.benzinga.com/general/entertainment/24/08/40411578/meta-ceo-mark-zuckerberg-commissions-statue-of-wife-priscilla-chan-sparks-online-buzz-bring">Priscilla Chan</a>, answered rapid-fire questions while offering a glimpse into their daily life. From sharing their favorite school subjects (Zuckerberg loves coding, biology and math) to talking about making homemade ice cream (from their own dairy cow, no less) with their kids. Zuckerberg even joked about losing a pair of mittens Chan made for him when they were teenagers.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The <a href="https://www.benzinga.com/news/24/01/36593131/science-takes-center-stage-at-czi-as-mark-zuckerberg-and-priscilla-chan-alter-philanthropic-course">Chan Zuckerberg Initiative</a> has been working on innovative health projects, such as developing microsensors to detect inflammation in the body. Zuckerberg highlighted their potential to help people live healthier lives, showcasing the couple's commitment to merging technology and philanthropy.
While the video celebrated the couple's efforts to advance education, health care and scientific research, Zuckerberg's growing watch collection caught some extra attention. Known for his simple wardrobe, his taste in watches is anything but basic. The Patek Philippe 5303R, originally retailing for $720,000, now commands an average selling price of $1.2 million. It joins other high-end pieces in Zuckerberg's collection, like the Bulgari Octo Finissimo Ultra COSC, which was spotted on his wrist earlier this year.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Addressing the Bunker Rumors</h2>
In addition to his nonprofit work and luxury watches, Zuckerberg recently clarified rumors surrounding a supposed <a href="https://www.benzinga.com/startups/24/01/36720135/mark-zuckerberg-spent-187-million-secretly-buying-1-600-acres-of-hawaii-land-and-now-he-is-reportedl">massive bunker</a> on his Hawaii compound. In an interview with Bloomberg, he addressed a WIRED report that suggested he was building a 5,000-square-foot bunker under his Kauai property.
"That's just like a little shelter," Zuckerberg said. "Whatever you want to call it, hurricane shelter, whatever. I think it got like, blown out of proportion as if like the whole ranch was some kind of doomsday bunker, which is just not true."
He explained that their <a href="https://www.benzinga.com/real-estate/24/06/39437900/mark-zuckerberg-owns-over-1-200-acres-of-land-including-a-hawaiian-doomsday-bunker-now-hes-building">Hawaii property, Koolau Ranch</a>, focuses on ranching and sustainability. "The Kauai thing is really fun," he shared. "We have this whole vertical integration plan where we're growing macadamia nuts to feed the macadamia meal and we're brewing beer because that helps [the cattle] eat more. That's fun."
Read Next:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Mark Zuckerberg Talks Non-Profit Achievements While Displaying A $1.2 Million Patek Philippe Watch

Barclays analyst Luke Sergott lowered the firm's price target on 10x Genomics (TXG) to $19 from $21 and keeps an Overweight rating on the shares. T...

10x Genomics price target lowered to $19 from $21 at Barclays

ARKK's holdings ranked by SA Quant Grades

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

With vast potential, contribution to rare disease discovery and management, and adoption of AI, the genomic research market is thriving. Hence, fundamentally solid genomic research stocks Agilent Technologies (A), Illumina (ILMN), and 10x Genomics (TXG) could be ideal buys. Read more... The rising risks towards human health are pushing the research and innovations in the genomic market, opening multi-faceted opportunities for the market. Also, the rapid adoption of technological advancements is increasingly accelerating its potential to cater to patients.
Against this backdrop, it could be wise to invest in fundamentally strong genomic research stocks Agilent Technologies, Inc. (<a href="https://stocknews.com/stock/A/">A</a>), Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>), and 10x Genomics, Inc. (<a href="https://stocknews.com/stock/TXG/">TXG</a>) with significant growth potential.
Genomics is revolutionizing modern healthcare and emerging as one of the most helpful technologies in today's world. Genomics has shown its ability to prevent, manage, and treat diseases, causing a major shift from conventional treatment methods to precision medicine in the healthcare sector.
Owing to factors like the growing incidence of cancer, growing research and development on genomics, supporting government initiatives, and the declining cost of sequencing, the demand for genomic research companies is on the rise. Also, increased demand for <a href="https://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html">personalized medicine</a> and tailored patient care and plans are navigating the market.
Fortune Business Insights forecast the global genomics market to grow from $30.75 billion in 2024 to $80.17 billion by 2032, exhibiting growth at a <a href="https://www.databridgemarketresearch.com/reports/global-genomics-market#:~:text=Genomics%20Market%20Analysis%20and%20Size&amp;text=Data%20Bridge%20Market%20Research%20analyses,period%20of%202023%20to%202030.">CAGR of 12.7%</a>. Essential factors contributing to the market growth include rising genomics applications, growing government support, and implementation of artificial intelligence (AI).
Given the industry's robust outlook, investing in fundamentally strong genomic research stocks A, ILMN, and TXG could be wise.
Let's discuss the fundamentals of these stocks in detail:
Agilent Technologies, Inc. (<a href="https://stocknews.com/stock/A/">A</a>)
A provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets globally. The company operates through three segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab.
On November 14, Agilent announced the innovative Mito-rOCR Assay Kit. Mito-rOCR is an easy and streamlined end-to-end solution that makes sophisticated analysis of mitochondrial function available to researchers of all skill levels with accuracy and ease.
This cost-effective and versatile kit allows researchers to easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies.
Also, on October 21, A unveiled its next-generation Agilent InfinityLab LC Series portfolio, consisting of 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems featuring the new Agilent InfinityLab Assist Technology, providing enhanced, built-in system assistance capabilities.
This technology elevates lab efficiency with enhanced automation, connectivity, and sustainability capabilities and allows labs to focus more on achieving results rather than on daily operation and maintenance tasks.
During the fourth quarter that ended October 31, 2024, A's <a href="https://www.investopedia.com/terms/r/revenue.asp">net revenue</a> increased 0.8% year-over-year to $1.70 billion, and its income from operations was $408 million. The company's non-GAAP net income and non-GAAP EPS came in at $418 million and $1.46, up 3.5% and 5.8% from the prior-year quarter, respectively.
Additionally, as of October 31, 2024, the company's total assets stood at $11.85 billion compared to $10.76 billion as of October 31, 2023.
According to the company's fiscal first-quarter 2025 outlook, A expects revenue in the range of $1.65 billion to $1.68 billion. Non-GAAP earnings per share are expected to range from $1.25 to $1.28.
Also, for the full year, the company expects revenue between $6.79 billion and $6.87 billion, representing a range of up 4.3% to 5.5% on a reported basis. Also, its non-GAAP earnings are expected to be $5.54 to $5.61 per share.
Analysts expect A's revenue and EPS for the second quarter (ending April 2025) to increase 5.1% and 7% year-over-year to $1.65 billion and $1.31, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters.
Shares of A have surged 5.2% over the past month and 10.5% over the past year to close the last trading session at $138.14.
A's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
A has a B grade for Quality. It is ranked #8 out of 41 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical – Diagnostics/Research</a> industry.
In addition to the POWR Ratings we've stated above, we also have A's ratings for Growth, Sentiment, Value, Momentum, and Stability. Get all ratings <a href="https://stocknews.com/stock/A/">here</a>.
Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN offers sequencing- and array-based solutions for genetic and genomic analysis internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, whole-genome sequencing kits, and targeted resequencing kits.
On November 19, ILMN announced that it will release TruSight&#x2122; Oncology 500 v2 (TSO 500 v2) in mid-2025. It is a new version of the company's flagship cancer research assay that enables comprehensive genomic profiling (CGP). The latest solution will enable comprehensive genomic profiling of tumors.
The TSO 500 v2 launch will expand ILMN's TruSight Oncology portfolio with its capability to assess hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample to facilitate therapy selection research.
On October 24, ILMN released its MiSeq&#x2122; i100 Series of sequencing systems, offering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs.
During the third quarter that ended September 30, 2024, ILMN reported revenue of $1.08 billion, and its operating profit grew 182.8% from the year-ago value to $741 million. The company's non-GAAP gross profit was $761 million, up 4% from the prior year's quarter.
Furthermore, ILMN's non-GAAP net income and EPS came in at $181 million and $1.14, indicating increases of 248.1% and 245.5% year-over-year, respectively.
For the fourth quarter of 2024, the company raised its guidance for Core Illumina's non-GAAP operating margin to a range of 21% to 21.5%. It expects Core Illumina revenue of $1.07 billion.
For fiscal year 2024, the company's Core Illumina non-GAAP EPS is expected to range from $4.05 to $4.15.
Street expects ILMN's revenue for the first quarter (ending March 2025) to increase marginally year-over-year to $1.08 billion, while its EPS is expected to grow 1015.7% year-over-year to $1, respectively. Furthermore, the company surpassed the consensus revenue estimates in all of the trailing four quarters.
ILMN's stock has gained 37.5% over the past six months and 52.5% over the past year to close the last trading session at $144.36.
ILMN's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Quality. ILMN is ranked #21 among 334 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/ILMN/">Click here</a> to access ILMN's ratings for Momentum, Value, Stability, and Sentiment.
10x Genomics, Inc. (<a href="https://stocknews.com/stock/TXG/">TXG</a>)
TXG is a life science technology company that develops and sells instruments, consumables, and software for analyzing biological systems internationally. The company offers chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
On October 31, TXG and Cure51, a French TechBio startup, announced that Cure51 will deploy 10x Genomics' Visium HD for its pioneering work to analyze the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches.
On October 15, TXG launched two new Chromium products intended to democratize access to single-cell analysis. The company's new offerings, GEM-X Flex and GEM-X Universal Multiplex, introduce significant improvements in performance, workflow, and cost-effectiveness, enabling more researchers to pursue single-cell analysis for more applications.
During the third quarter that ended September 30, 2024, TXG's total consumables revenue increased 10.3% year-over-year to $126.20 million, and its total revenue came in at $151.65 million. The company's gross profit was $106.39 million for the quarter, up 11.4% from the prior year's quarter.
In addition, the company's cash and cash equivalents were $398.16 million as of September 30, 2024, compared to $359.28 million as of December 31, 2023.
The company updated its financial guidance for the full year 2024. The company now expects revenue in the range of $595 million to $605 million.
Street expects TXG's revenue for the first quarter (ending March 2025) to increase 1.2% year-over-year to $142.72 million. For the fiscal year 2025, its revenue is expected to grow 6% year-over-year to $635.36 million.
TXG's stock has declined marginally over the past month to close the last trading session at $15.48.
TXG's POWR Ratings reflect its robust outlook. The stock has a B grade for Value and Quality. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, TXG is ranked #26 among 63 stocks.
<a href="https://stocknews.com/stock/TXG/">Click here</a> to access additional ratings of TXG for Momentum, Growth, Sentiment, and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
A shares were trading at $138.04 per share on Friday afternoon, down $0.10 (-0.07%). Year-to-date, A has declined -0.21%, versus a 28.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/a-ilmn-txg-3-genomic-research-companies-pioneering-personalized-medicine/>3 Genomic Research Companies Pioneering Personalized Medicine</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomic Research Companies Pioneering Personalized Medicine

Worst performing stocks for tax loss selling – Wolfe

10x Genomics wins permanent injunction against NanoString

In an order posted to the site of the U.S. District Court for the District of Delaware, the court stated: "10x Genomics (TXG), Inc. and Prognosys B...

Court grants 10x Genomics' motion in part in patent suit against NanoString

10x Genomics (TXG) announced it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx produc...

10x Genomics secures permanent injunction in Bruker patent infringement lawsuit

20:08 EST Cathie Wood's ARK Investment buys 36K shares of 10x Genomics (TXG) today Published first on TheFly – the ultimate source for real-time, m...

Cathie Wood's ARK Investment buys 36K shares of 10x Genomics today

Bruker plans to file for a stay of NanoString GeoMX injunction ruling

ACHC

ACHR

ACLS

AGCO

ALGM

AMKR

AMZN

APLS

ARKF

ARKQ

ARKX

ATKR

AVTR

BIIB

BMRN

BRBR

BRKR

CERS

CLVT

CNXC

COLD

DINO

DKNG

DXCM

ENPH

EXAS

FIVN

FLNC

ILMN

INTC

IPGP

MCHP

MDXH

MRNA

MYGN

NEOG

NTLA

OPCH

PACB

PINS

PRME

PTEN

QDEL

QRVO

REGN

REXR

RVTY

SEDG

SGRY

SOFI

STNE

SWKS

SYNA

VCYT

VERV

WOLF

XRAY

Press Releases

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics Reports Third Quarter 2024 Financial Results

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Comments

10x Genomics

10x Genomics (TXG) 옵션

10x Genomics (NASDAQ:TXG) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌